HOME >> MEDICINE >> NEWS
Light-weight heparin has heavy-weight results in heart attack treatment

DALLAS, Heart attack patients treated with the blood-thinner enoxaparin a low molecular weight heparin plus a clot dissolver were significantly less likely to die or have repeat heart attacks within 30 days compared to patients who received unfractionated heparin (UFH), according to a Rapid Track article in todays Circulation: Journal of the American Heart Association.

Patients in the study had what are known as ST-segment elevation myocardial infarctions, which are the most severe type of heart attack. We have very encouraging data but the evidence is not yet sufficient to say that enoxaparin should be standard treatment for severe heart attacks, says Elliott Antman, M.D., associate professor of medicine at Harvard Medical School and director of the coronary care unit of Brigham and Womens Hospital in Boston. However, the data suggest we should pursue a larger clinical trial.

Enoxaparin previously has been shown to be superior to unfractionated heparin (another blood thinner) for patients with milder heart attacks (non-ST segment elevation). It can be given as a simple injection, rather than the continuous infusion required with UFH, and it does not require frequent testing of the patients blood clotting status.

The researchers report their findings from the ENTIRE-TIMI 23 study. This international study involved 483 patients who presented with severe heart attacks at hospitals in the United States and Europe. Participants were randomly assigned either standard reperfusion with a full dose of the clot-dissolving drug tenecteplase (TNK) or combination therapy with abciximab and a half dose of TNK and either unfractionated heparin (UFH) or enoxaparin. Abciximab is a drug that helps keep blood platelets from sticking together to form clots.

The study was designed to evaluate enoxaparin as adjunctive treatment with various forms of reperfusion therapies (TNK, abciximab). To evaluate reperfusion (blood flow) researchers used the TIMI
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
4-Mar-2002


Page: 1 2

Related medicine news :

1. The protective effects of heparin in preventing miscarriages in lupus patients
2. Newer formulation of heparin improves outcomes for suspected heart attack patients
3. New studies show mixed results on epilepsy drugs and birth defects
4. Study of obese diabetics explains why low-carb diets produce fast results
5. Sharing clinical trial results with participants may be beneficial
6. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
7. Similar results found in both older and younger patients undergoing weight-loss surgery
8. OHSU researcher says FDA could broaden access to results of clinical drug trials
9. Kinder, gentler procedure gives superior results for stem cell transplants
10. Good results with only one egg in in-vitro fertilization
11. Holiday feasting could sabotage liposuction results

Post Your Comments:
(Date:1/22/2015)... Liberty University has received accreditation for its ... the Council for Accreditation of Counseling & Related Educational ... Center for Counseling & Family Studies , is under the ... new School of Behavioral Sciences. Prior to the formation of ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
(Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... BOSTON , January 23, 2015 ... development company, is delighted to announce that the Malcolm ... Miles Congreve (Vice President of Chemistry), Fiona ... Weir (Chief Executive Officer and co-founder) for the seminal ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
Cached News: